Findings showed after 52 weeks, significant improvements in 2MWD and 6MWD were seen with Flebogamma 5% DIF 1mg/kg compared with placebo. Topline data were announced from a phase 2/3 trial evaluating ...

March 6, 2006 (Miami Beach) — A subcutaneous formulation of immunoglobulin replacement therapy ( Vivaglobin) produces results in primary immune deficiency diseases (PIDD) that are similar to those for ...

Intravenous immunoglobulin therapy (IVIG) is a critical treatment modality in the management of a spectrum of immunodeficiencies, autoimmune disorders, and inflammatory conditions. Derived from pooled ...

Intravenous immunoglobulin (IVIG) is used to replenish immunoglobulins in hypogammaglobulinemia (HG) caused by hematologic malignancies (HM) or their treatment (autologous stem-cell transplantation ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

For the last eight years, Leslie MacGregor from Newton, Massachusetts, has been getting intravenous infusions every month. The treatment is called immunoglobulin, and it bolsters her defective immune ...

A clinical trial has found that the combination of remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, is not more effective than ...

In a recent study posted to the medRxiv* preprint server, researchers comparatively evaluated antibody (Ab) responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among ...

A national shortage of some brands of Intravenous Immunoglobulin, a life-improving and sometimes life-saving treatment of antibodies, is impacting patients in places from Boston to Virginia.

The Key Intravenous Immunoglobulin Companies in the market include - Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions, and others. DelveInsight’s “Intravenous Immunoglobulin Market ...